They compared histological specimens from the initial resection with specimens from the repeat resection by means of pyrosequencing assay for Kirsten rat sarcoma (KRAS) mutations and immunohistochemistry for mucin (MUC) 1 and MUC2 to distinguish between cancer recurrence and new primary lesion. This evidence concerns the gene KRAS and cancer.